SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

NCT00796731 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
77
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi